Gouty arthritis, also known as gout, is a type of arthritis that attack joints, and with time it also attacks tendons and other tissues. It is caused by increase in the uric acid in the blood. Alcohol abuse, obesity and high consumption of diuretics can increase the risk of developing gout. The most common symptoms of gout include swelling, pain and rudeness. The disease can be treated by ibuprofen or another anti-inflammatory medicine. CymaBay Therapeutics, Inc. is in the process of developing Arhalofenate for the treatment of gout. The drug candidate is being developed as a SLC22A12 protein inhibitor. Some of the companies having a pipeline of gouty arthritis include Relburn-Metabolomics, Inc., IFM Therapeutics and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.